Wilk Technologies Ltd
TTASE:WILK566.60
ILA
+6.30
(+1.12%)
ISIN
IL0002780109
Return %
Stock
S&P 500
1Y
198.29
14.20
3Y
-69.45
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Tomer Aizen
- Full Time Employees
- 3
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Prof. Hillel and Hanan Oppenheimer 4 Rehovot TA Israel 7670135
- IPO Date
- Jan 8, 1992
- Website
- wilkismilk.com
- Similar Companies
- Business
- Wilk Technologies Ltd Wilk Technologies Ltd is an Israel-based biotechnology company that researches, develops, and produces cell-based cultured milk and dairy products as animal-free alternatives to conventional animal milk and human breast milk. Incorporated in 1986 and headquartered in Rehovot, the company, formerly known as Biomilk Ltd until its name change in November 2021, focuses on precision fermentation technologies derived from mammary epithelial cells to produce authentic milk components including fats, proteins, lactose, oligosaccharides, and minerals; its pipeline targets dairy products such as yogurt, sour milk, and other cultured dairy items, as well as human milk fat for infant formula applications to address nutritional needs for preterm infants and breastfeeding shortages. Wilk Technologies operates primarily in the foodtech and biotech sectors, serving global markets with an emphasis on sustainable, eco-friendly solutions that reduce environmental impacts like water usage and greenhouse gas emissions associated with traditional dairy farming; the company employs a small team of approximately four and maintains R&D facilities in Israel. The company's core offerings include cell-cultured animal milk for everyday dairy consumption and healthy diets; cell-based human milk components optimized for infant nutrition, including sterile formulations that mimic natural breast milk composition (87% water, 7% lactose, 4.2% fats, 1.1% proteins, 0.5% oligosaccharides, 0.1% minerals); and innovative dairy prototypes such as the world's first hybrid yogurt incorporating lab-grown milk fat, validated by external labs for chemical and biological standards while retaining macro- and micronutrients like vitamins D, E, calcium, and anti-inflammatory properties. In recent developments, Wilk Technologies achieved a milestone in 2022-2023 by launching the first cell-based yogurt with cultured milk fat, demonstrating scalable production of functional dairy ingredients and advancing toward commercial dairy products without animal reliance. The company secured a ILS 12.5 million funding round in May 2023 led by Danone Manifesto Ventures (ILS 7 million), with participation from Steakholder Foods Ltd., Tara (via Central Bottling Company/Coca-Cola Israel), and other investors, alongside a strategic collaboration with Danone to explore joint development of breast milk substitutes for infant formula and potential commercial operations in Europe and the US. Earlier partnerships include a 2021 strategic agreement with Central Bottling Company for product development based on cultured milk technology, supported by a $2 million investment, while ongoing efforts emphasize increasing production capacity, fat separation methods, and integration into infant formulas to meet rising demand for sustainable dairy amid projected 56% global food consumption growth by 2050.